Sumiko Gomi and Catherine Bates
Influenza virus infection increases susceptibility to bacterial infection and mortality, which the antiviral drug, Tamiflu, is reported to have the possible benefit of reducing both. It was hypothesized that Tamiflu induces gut microbiome composition changes in Tamiflu- or PBS-treated mice after Influenza A Virus (IAV) and Methicillin-resistant Staphylococcus aureus (MRSA) coinfection. After IAV-MRSA coinfection, feces were collected from Tamiflu or PBS-treated mice. In this project, the bacterial DNA was extracted from the feces and was analyzed by qPCR using phylum and genus specific primers to examine changes in the gut microbiota. The phylum Firmicutes showed the treatment group increased in relative abundance by 7% and the control decreased by 7%. The phylum Bacteroidetes showed the treatment group's relative abundance showed no change and the control increased by 25%. When looking at the phylum, Tenericutes and TM7, there was a spike in relative abundance expression the days immediately following MRSA infection in the control, but not the Tamiflu treatment group. These results suggest the administration of Tamiflu in mice coinfected with IAV and MRSA leads to different gut microbiome composition changes when compared with mice that did not receive the Tamiflu treatment.
Meyer, Andrea C. and Gomi, Sumiko, "Dynamic Changes in the Gut Microbiome Associated with Influenza A Virus, MRSA Coinfection and Tamiflu Administration" (2021). 2021 Undergraduate Research Showcase. 37.